Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
12 hedge funds and large institutions have $727K invested in Statera Biopharma, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
60% more capital invested
Capital invested by funds: $454K → $727K (+$273K)
20% less funds holding
Funds holding: 15 → 12 (-3)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$8.99K |
| 2 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$645 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$6K |
| 3 |
BlackRock
New York
|
-$1.32K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $493K | +$8.99K | +6,100 | +2% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $176K | – | – | – |
|
3
Geode Capital Management
Boston,
Massachusetts
| $27K | – | – | – |
|
|
4
BlackRock
New York
| $23K | -$1.32K | -896 | -6% |
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $6K | – | – | – |
|
|
6
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $2K | +$645 | +438 | New |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$15K | -15,268 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$6K | -5,981 | Closed |
|
|
9
Wells Fargo
San Francisco,
California
| – | -$3 | -2 | -4% |
|
STAB Hedge Fund Activity: Q1 2019 in Review
12 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q1 2019, worth a combined $727K — up 60% from $454K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of STAB and 1 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $8.99K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $15K sold.
- 12 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q1 2019, down from 15 in Q4 2018.
- Funds reported $727K of Statera Biopharma, Inc. Common Stock stock for Q1 2019, up 60% quarter-over-quarter.
- 1 fund opened new Statera Biopharma, Inc. Common Stock positions in Q1 2019 and 4 closed out, a net change of -3 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q1 2019 was Renaissance Technologies, an estimated $8.99K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q1 2019 was Susquehanna International Group, an estimated $15K sold.
Based on aggregated 13F filings for Q1 2019.